Publications: Dr Manish Saxena

Saxena M, Aswad A, Badariene J, Karim A, Sia YT, Stiglitz D, Makarova N, Havasi A et al. ( 2024 ) . Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive . European Heart Journal vol. 45 , ( Supplement_1 )

Bloch MJ, Kirtane AJ, Azizi M, Mahfoud F, Basile J, Daemen J, Saxena M, Thackeray L et al. ( 2024 ) . 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO . Hypertension Research1 - 6 .

Greene SJ, Böhm M, Bozkurt B, Butler J, Cleland JGF, Coats AJS, Desai NR, Grobbee DE et al. ( 2024 ) . Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry . Journal of Cardiac Failure

Unverdorben M, Colonna P, Jin J, Köhler S, Santamaria A, Saxena M, Borrow A, Chen C et al. ( 2024 ) . Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program . Clinical and Applied Thrombosis/Hemostasis vol. 30 ,

Saxena M ( 2024 ) . Vaccines against angiotensin receptors as a potential treatment for hypertension . Journal of Hypertension vol. 42 , ( 7 )

Colonna P, Souza J, Saxena M, Vanassche T, Santamaria A, Jin J, Kohler S, Borrow A et al. ( 2024 ) . Management of edoxaban therapy in patients undergoing emergency/urgent procedures: a subanalysis of the global, prospective, observational, multinational EMIT-AF/VTE programme . EP Europace vol. 26 , ( Supplement_1 )

Saxena M, Aswad A, Badariene J, Kazi F, Karns AD, Neutel JM, Park W, Stiglitz D et al. ( 2024 ) . ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY . Journal of Hypertension vol. 42 , ( Suppl 1 )

Hall CV, Twelves JL, Saxena M, Scapozza L, Gurry T ( 2024 ) . Effects of a diverse prebiotic fibre supplement on HbA1c, insulin sensitivity and inflammatory biomarkers in pre-diabetes: a pilot placebo-controlled randomised clinical trial . British Journal Of Nutrition vol. 132 , ( 1 ) 68 - 76 .

Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, Schmieder RE, Janas AJ et al. ( 2024 ) . Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial . Circulation vol. 149 , ( 24 ) 1875 - 1884 .

SAXENA M, Desai AS, Azizi M, Gupta A, Lee J, Stiglitz D, Makarova N, Goyal N et al. ( 2024 ) . CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION . Journal of the American College of Cardiology vol. 83 , ( 13 )

Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N et al. ( 2024 ) . RNA Interference With Zilebesiran for Mild to Moderate Hypertension . JAMA vol. 331 , ( 9 ) 740 - 749 .

Magavern EF, Kapil V, Saxena M, Gupta A, Caulfield MJ ( 2024 ) . Use of Genomics to Develop Novel Therapeutics and Personalize Hypertension Therapy . Arteriosclerosis Thrombosis and Vascular Biology vol. 44 , ( 4 ) 784 - 793 .

Collier DJ, Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V et al. ( 2024 ) . Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial) . Journal of the American Heart Association vol. 13 , ( 4 )

Bertog SC, Sharma A, Hering D, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V et al. ( 2024 ) . Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter . Renal Denervation , Springer Nature

Saxena M, Lobo MD ( 2024 ) . What Needs to Be Shown Before Renal Denervation Can Be Used in Clinical Practice? . Renal Denervation , Springer Nature

von Heymann C, Unverdorben M, Colonna P, Santamaria A, Saxena M, Vanassche T, Köhler S, Borrow AP et al. ( 2023 ) . Management of edoxaban therapy and clinical outcomes in patients undergoing major or nonmajor surgery: a subanalysis of the EMIT-AF/VTE study . Thrombosis Journal vol. 21 , ( 1 )

Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Fareed K, Kidwai A, Kaye C et al. ( 2023 ) . Intravenous Vitamin C for Patients Hospitalized With COVID-19 . JAMA vol. 330 , ( 18 ) 1745 - 1759 .

Azizi M, Sharp ASP, Fisher NDL, Weber MA, Lobo MD, Daemen J, Lurz P, Mahfoud F et al. ( 2023 ) . Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program . Circulation vol. 149 , ( 10 ) 747 - 759 .

Azizi M, Saxena M, Wang Y, Devireddy C, Jenkins J, Fisher N, Schmieder R, Mahfoud F et al. ( 2023 ) . TCT-398 Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: 6-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial . Journal of the American College of Cardiology vol. 82 , ( 17 )

Santamaria A, Chen C, Colonna P, von Heymann C, Saxena M, Vanassche T, Jin J, Unverdorben M ( 2023 ) . Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE . Clinical and Applied Thrombosis/Hemostasis vol. 29 ,

Lobo MD, Rull G, Saxena M, Kapil V ( 2023 ) . Selecting patients for interventional procedures to treat hypertension . Blood Pressure vol. 32 , ( 1 )

Pathak A, Rudolph UM, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, Schmieder RE, Sievert H et al. ( 2023 ) . Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications . EuroIntervention vol. 19 , ( 7 ) 602 - 611 .

Chen C, Saxena M, von Heymann C, Vanassche T, Jin J, Lersch R, Köhler S, Santamaria A et al. ( 2023 ) . Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database . BDJ Open vol. 9 , ( 1 )

Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, Lobo MD, Lurz P et al. ( 2023 ) . Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials . JAMA Cardiology vol. 8 , ( 5 ) 464 - 473 .

Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Fareed K, Kidwai A, Kaye C et al. ( 2023 ) . Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19 . JAMA vol. 329 , ( 14 ) 1183 - 1196 .

Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE et al. ( 2023 ) . Endovascular Ultrasound Renal Denervation to Treat Hypertension . JAMA vol. 329 , ( 8 ) 651 - 661 .

Wiffen L, Brown T, Maczka AB, Kapoor M, Pearce L, Chauhan M, Chauhan AJ, Saxena M et al. ( 2023 ) . Measurement of Vital Signs by Lifelight Software in Comparison to Standard of Care Multisite Development (VISION-MD): Protocol for an Observational Study . JMIR Research Protocols vol. 12 ,

Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, Masood S, Kaye C et al. ( 2023 ) . Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial . JAMA vol. 329 , ( 1 ) 39 - 51 .

Azizi M, Mahfoud F, Weber MA, Sharp ASP, Schmieder RE, Lurz P, Lobo MD, Fisher NDL et al. ( 2022 ) . Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation . JAMA Cardiology vol. 7 , ( 12 ) 1244 - 1252 .

Heiden E, Jones T, Maczka AB, Kapoor M, Chauhan M, Wiffen L, Barham H, Holland J et al. ( 2022 ) . Measurement of Vital Signs Using Lifelight Remote Photoplethysmography: Results of the VISION-D and VISION-V Observational Studies . JMIR Formative Research vol. 6 , ( 11 )

Rader F, Kirtane AJ, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al. ( 2022 ) . Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial . EuroIntervention vol. 18 , ( 8 ) e677 - e685 .

Bloch M, Kirtane A, Mahfoud F, Azizi M, Basile J, Daemen J, Saxena M, Gosse P et al. ( 2022 ) . TCT-212 Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial . Journal of the American College of Cardiology vol. 80 , ( 12 ) b85 - b86 .

Saxena M, Von Heymann C, Santamaria A, Jin J, Chen C, Borrow A, Vanassche T, Unverdorben M et al. ( 2022 ) . Management of edoxaban in patients undergoing multiple procedures: a subanalysis of the EMIT-AF/VTE program . EP Europace vol. 24 , ( Supplement_1 )

Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, Masood S, Kaye C et al. ( 2022 ) . Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19 . JAMA vol. 327 , ( 13 ) 1247 - 1259 .

Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V, Patel M et al. ( 2022 ) . WHOSE DOSE IS IT ANYWAY? INDIVIDUAL PATIENT DOSE-RESPONSE CURVES FROM THE REMOTE-CARE PERSONAL-COVIDBP TRIAL . Journal of the American College of Cardiology vol. 79 , ( 9 )

Collier D, Taylor M, Godec T, Shiel J, James R, Chowdury Y, Ebano P, Monk V et al. ( 2022 ) . Personalized electronic record supported optimisation when alone for patients with hypertension- pilot study for remote medical management of hypertension during the Covid-19 pandemic (personal covidBP) . JOURNAL OF HUMAN HYPERTENSION . vol. 36 , 8 - 8 .

Bloch M, Kirtane A, Mahfoud F, Azizi M, Basile J, Daemen J, Saxena M, Gosse P et al. ( 2022 ) . Twenty-Four Month Results in Patients With Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial . JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY . vol. 80 , B85 - B86 .

Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Jin J, Chen C et al. ( 2021 ) . Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program . Pacing and Clinical Electrophysiology vol. 45 , ( 1 ) 83 - 91 .

von Heymann C, Unverdorben M, Colonna P, Ortiz AS, Saxena M, Vanassche T, Weitz JI, Wilkins R et al. ( 2021 ) . Management of Edoxaban Therapy in Patients Undergoing Major Surgery: A Sub-Analysis of the Prospective, Observational, Multinational Emit-AF/VTE Study . Blood vol. 138 , ( Supplement 1 )

Linschoten M, Uijl A, Schut A, Jakob CEM, Romão LR, Bell RM, McFarlane E, Stecher M et al. ( 2021 ) . Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries . European Heart Journal vol. 43 , ( 11 ) 1104 - 1120 .

Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM et al. ( 2021 ) . Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial . JAMA vol. 326 , ( 17 ) 1690 - 1702 .

Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al. ( 2021 ) . TCT-369 Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial . Journal of the American College of Cardiology vol. 78 , ( 19 )

Fisher NDL, Kirtane AJ, Daemen J, Rader F, Lobo MD, Saxena M, Abraham J, Schmieder RE et al. ( 2021 ) . Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial . Journal of Hypertension vol. 40 , ( 2 ) 221 - 228 .

Vanassche T, Colonna P, Santamaria A, Chen C, Von Heymann C, Jin J, Saxena M, Jiang W et al. ( 2021 ) . Periprocedural anticoagulation management in edxoaban patients undergoing catheter-based cardiovascular procedures: analyses of the noninterventional global EMIT study . EP Europace vol. 23 , ( Supplement_3 )

Unverdorben M, Colonna P, Von Heymann C, Santamaria A, Saxena M, Vanassche T, Wilkins R, Chen C ( 2021 ) . Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study . EP Europace vol. 23 , ( Supplement_3 )

Saxena M, Schmieder RE, Kirtane AJ, Mahfoud F, Daemen J, Basile J, Lurz P, Gosse P et al. ( 2021 ) . Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study . Journal of Human Hypertension vol. 36 , ( 7 ) 629 - 639 .

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A et al. ( 2021 ) . Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial . The Lancet vol. 397 , ( 10293 ) 2476 - 2486 .

Saxena M, Kermali M, Balawon A, Pheby J, Benu E, Piniera B, Low D, Mathur A et al. ( 2021 ) . COLLATERAL BENEFITS OF PARTICIPATION IN CLINICAL RESEARCH: INSIGHTS FROM A RESISTANT HYPERTENSION TRIAL SCREEN OUT POPULATION . Journal of Hypertension . vol. 39 ,

Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R et al. ( 2021 ) . Correction to: Elderly patients with atrial fibrillation in routine clinical practice: peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study . BMC Cardiovascular Disorders vol. 21 , ( 1 )

Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, Saxena M, Levy T et al. ( 2021 ) . Durability of Reduced Office-Measured Blood Pressure and Antihypertensive Medication Use After Ultrasound Renal Denervation: 24-Month Results From the RADIANCE-HTN SOLO Trial . JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY . vol. 78 , B152 - B152 .

Maniero C, Julu P, Shah M, Wolff C, Kapil V, Rull G, Gupta A, Saxena M et al. ( 2021 ) . Dysregulation of central respiratory modulation of cardiac vagal tone is a novel, early sign of dysautonomia in patients with α-synucleinopathies . JOURNAL OF HUMAN HYPERTENSION . vol. 35 , 16 - 16 .

Gosse P, Cremer A, Kirtane AJ, Lobo MD, Saxena M, Daemen J, Wang Y, Stegbauer J et al. ( 2020 ) . Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation . Hypertension vol. 77 , ( 2 ) 529 - 536 .

Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, Wang Y, Saxena M et al. ( 2020 ) . 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation . JACC Cardiovascular Interventions vol. 13 , ( 24 ) 2922 - 2933 .

Unverdorben M, von Heymann C, Santamaria A, Saxena M, Vanassche T, Jin J, Laeis P, Wilkins R et al. ( 2020 ) . Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study . BMC Cardiovascular Disorders vol. 20 , ( 1 )

Feyz L, Wang Y, Pathak A, Saxena M, Mahfoud F, Sanghvi K, Peterson R, Kirtane AJ et al. ( 2020 ) . Using social media to recruit study participants for a randomized trial for hypertension . European Heart Journal - Digital Health vol. 1 , ( 1 ) 71 - 74 .

Santamaria A, Colonna P, von Heymann C, Saxena M, Vanassche T, Jin J, Wilkins R, Chen C et al. ( 2020 ) . Periprocedural Interruption of Edoxaban in Real World Setting: Results from the Emit AF/VTE Study . Blood vol. 136 , ( Supplement 1 ) 13 - 14 .

Bertog S, Sharma A, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V, Weber MA et al. ( 2020 ) . Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter . Cardiovascular Revascularization Medicine vol. 24 , 77 - 86 .

Colonna P, von Heymann C, Santamaria A, Saxena M, Vanassche T, Wolpert D, Laeis P, Wilkins R et al. ( 2020 ) . Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT‐AF/VTE study . Clinical Cardiology vol. 43 , ( 7 ) 769 - 780 .

Saxena M, Kermali M, Balawon A, Pheby J, Benu E, Piniera B, Low D, Mathur A et al. ( 2020 ) . Collateral benefits of participation in clinical research: insights from a resistant hypertension trial screen out population . JOURNAL OF HUMAN HYPERTENSION . vol. 34 ,

Lobo MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, Bent C, Chapman N et al. ( 2019 ) . Joint UK societies’ 2019 consensus statement on renal denervation . Heart vol. 105 , ( 19 )

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, Sharp ASP, Bloch MJ et al. ( 2019 ) . Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial . Circulation vol. 139 , ( 22 ) 2542 - 2553 .

Azizi M, Schmieder R, Mahfoud F, Weber M, Daemen J, Lobo M, Sharp A, Basile J et al. ( 2019 ) . TREATMENT-BLINDED MEDICATION TITRATION FOR HYPERTENSION CONTROL FOLLOWING RANDOMIZATION TO ENDOVASCULAR ULTRASOUND RENAL DENERVATION OR A SHAM PROCEDURE . Journal of the American College of Cardiology vol. 73 , ( 9 )

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE et al. ( 2019 ) . Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA . Circulation vol. 139 , ( 3 ) 351 - 361 .

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M et al. ( 2019 ) . Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial . JAMA vol. 321 , ( 1 ) 69 - 79 .

Sharp ASP, Saxena M, Lobo MD ( 2018 ) . Renal artery sympathetic denervation: Back on track! . European Heart Journal vol. 39 , ( 46 ) 4056 - 4057 .

Saxena M, Shour T, Shah M, Wolff CB, Julu POO, Kapil V, Collier DJ, Ng FL et al. ( 2018 ) . Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success . J Am Heart Assoc vol. 7 , ( 12 )

Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, Ford I, Cruickshank JK et al. ( 2018 ) . Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies . Lancet Diabetes Endocrinol vol. 6 , ( 6 ) 464 - 475 .

Saxena M, Sobotka P, Balmforth P, Mathur A, Jain A, Rensing B, Lobo M ( 2018 ) . IMMEDIATE, SIGNIFICANT DECLINE IN CENTRAL AND PERIPHERAL BLOOD PRESSURE WITH CENTRAL ARTERIAL VENOUS ANASTOMOSIS . Journal of Hypertension . vol. 36 ,

BROWN MJ ( 2018 ) . Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study . Lancet Diabetes and Endocrinology vol. 6 , ( 6 ) 464 - 475 .

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ et al. ( 2018 ) . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial . The Lancet vol. 391 , ( 10137 ) 2335 - 2345 .

Mukhtar O, Cheriyan J, Cockcroft JR, Collier D, Coulson JM, Dasgupta I, Faconti L, Glover M et al. ( 2018 ) . A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial . American Heart Journal vol. 204 , 102 - 108 .

Schmieder RE, Ott C, Toennes SW, Bramlage P, Gertner M, Dawood O, Baumgart P, O'Brien B et al. ( 2018 ) . Phase II randomized sham-controlled study of renal denervation for individuals with uncontrolled hypertension – WAVE IV . Journal of Hypertension . vol. 36 , 680 - 689 .

MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, Ford I, Sever P et al. ( 2017 ) . Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial . J Am Heart Assoc vol. 6 , ( 11 )

Lobo MD, Ott C, Sobotka PA, Saxena M, Stanton A, Cockcroft JR, Sulke N, Dolan E et al. ( 2017 ) . Central Iliac Arteriovenous Anastomosis for Uncontrolled Hypertension . Hypertension vol. 70 , ( 6 ) 1099 - 1105 .

Schmieder RE, Ott C, Toennes S, Gertner M, Dawood O, Saxena M, O’Brien B, Lobo M ( 2017 ) . [LB.01.02] PHASE II RANDOMIZED SHAM-CONTROLLED STUDY OF RENAL DENERVATION FOR SUBJECTS WITH UNCONTROLLED HYPERTENSION – WAVE IV . Journal of Hypertension . vol. 35 ,

Saxena M, Shour T, Shah M, Wolff C, Collier DJ, Kapil V, Balawon A, Pheby JM et al. ( 2017 ) . [LB.03.06] ATTENUATION OF SPLANCHNIC AUTOTRANSFUSION FOLLOWING NON-INVASIVE ULTRASOUND RENAL DENERVATION . Journal of Hypertension . vol. 35 , e77 - e78 .

Ormiston J, Neuzil P, O’brien B, Saxena M, Schmieder RE, Gertner M, Dawood O, Lobo MD ( 2017 ) . [PP.15.25] REDO RENAL DENERVATION WITH NON-INVASIVE THERAPEUTIC ULTRASOUND . Journal of Hypertension . vol. 35 ,

Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Worthley S ( 2017 ) . [PP.15.26] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS . Journal of Hypertension . vol. 35 ,

SAXENA M, Shour T, Sobotka P, Jain A, Collier DJ, Hamshere S, Mathur A, Knight C et al. ( 2017 ) . [PP.24.26] ANTIHYPERTENSIVE EFFECTS OF A CENTRAL ARTERIOVENOUS ANASTOMOSIS ARE MEDIATED THROUGH PROFOUND REDUCTION IN SYSTEMIC VASCULAR RESISTANCE . Journal of Hypertension . vol. 35 , e293 - e294 .

Saxena M, Shour T, Shah M, Wolff C, Collier DJ, Kapil V, Balawon A, Pheby JM et al. ( 2017 ) . Attenuation of splanchnic autotransfusion following non-invasive ultrasound renal denervation: a novel marker of procedural success . JOURNAL OF HUMAN HYPERTENSION . vol. 31 , 679 - 680 .

Ott C, Lobo MD, Sobotka PA, Mahfoud F, Stanton A, Cockcroft J, Sulke N, Dolan E et al. ( 2016 ) . Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension . J Am Heart Assoc vol. 5 , ( 12 )

Floyd CN, Adeel MY, Wolff CB, Julu P, Shah M, Collier DJ, Saxena M, Brier T et al. ( 2016 ) . First-in-man treatment of severe blood pressure variability with baroreflex activation therapy . International Journal of Cardiology vol. 220 , Article C , 577 - 579 .

Lobo MD, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al. ( 2016 ) . [OP.4C.04] SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION . Journal of Hypertension vol. 34 , ( &NA; )

Lobo MD, Adeel MY, Wolff CB, Julu PO, Shah M, Collier DM, Saxena M, Floyd C et al. ( 2016 ) . [OP.8D.02] FIRST IN MAN TREATMENT OF SEVERE BP VARIABILITY WITH BAROREFLEX ACTIVATION THERAPY . J Hypertens vol. 34 Suppl 2 , e105 - e105 .

Lobo M, Saxena M, Sobotka PA, Ott C, Dolan E, Foran J, Furniss SS, Cockcroft J et al. ( 2016 ) . [OP.LB.02.04] CENTRAL ILIAC ARTERIOVENOUS ANASTOMOSIS FOR UNCONTROLLED HYPERTENSION . Journal of Hypertension vol. 34 , ( &NA; ) e78 - e79 .

Lobo MD, Montarello J, Saxena M, Jain AK, Walters D, Pincus M, Worthley SG ( 2016 ) . [PP.26.11] RENAL DENERVATION USING THE ENLIGHTN RENAL DENERVATION SYSTEM IN ALTERNATIVE HYPERTENSIVE POPULATIONS . Journal of Hypertension . vol. 34 ,

Wolff C, Julu PO, Collier DJ, Saxena M, Kapil V, Shah M, Eftychiou S, Mills E et al. ( 2016 ) . [PP.38.09] EFFECTS OF MILD DYNAMIC EXERCISE ON CIRCULATORY AND AUTONOMIC FUNCTION IN HEALTHY VOLUNTEERS . Journal of Hypertension . vol. 34 , e351 - e352 .

Saxena M, Sobotka PA, Hamshere SM, Jain A, Mathur A, Knight C, Collier DJ, Lobo MD ( 2016 ) . Antihypertensive effects of a central arteriovenous anastomosis are mediated through profound reduction in systemic vascular resistance . Circulation: Cardiovascular Interventions vol. 9 , ( 8 )

Ng FL, Saxena M, Mahfoud F, Pathak A, Lobo MD ( 2016 ) . Device-based Therapy for Hypertension . Curr Hypertens Rep vol. 18 , ( 8 ) 61 - 61 .

De Jager RL, Sanders MF, Bots ML, Lobo MD, Ewen S, Beeftink MMA, Böhm M, Daemen J et al. ( 2016 ) . Renal denervation in hypertensive patients not on blood pressure lowering drugs . Clinical Research in Cardiology vol. 105 , ( 9 ) 755 - 762 .

Saxena M, Antoniou S, Hamedi N, Robinson P, Singh H, Mukhtar O, Kapil V, Lobo MD ( 2016 ) . Multiple drug-intolerant hypertension: a case series utilising a novel-treatment algorithm . British Journal of General Practice vol. 66 , ( 645 ) e285 - e287 .

Burchell AE, Chan K, Ratcliffe LEK, Hart EC, Saxena M, Collier DJ, Jain AK, Mathur A et al. ( 2016 ) . Controversies Surrounding Renal Denervation: Lessons Learned From Real‐World Experience in Two United Kingdom Centers . Journal of Clinical Hypertension vol. 18 , ( 6 ) 585 - 592 .

Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD ( 2016 ) . Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm . Journal of Clinical Hypertension vol. 18 , ( 2 ) 129 - 138 .

Wolff CB, Collier DJ, Shah M, Saxena M, Brier TJ, Kapil V, Green D, Lobo M ( 2016 ) . A Discussion on the Regulation of Blood Flow and Pressure . Advances in Experimental Medicine and Biology vol. 876 , 129 - 135 .

Antoniou S, Saxena M, Hamedi N, de Cates C, Moghul S, Lidder S, Kapil V, Lobo MD ( 2016 ) . Management of Hypertensive Patients With Multiple Drug Intolerances: A Single-Center Experience of a Novel Treatment Algorithm . JOURNAL OF CLINICAL HYPERTENSION vol. 18 , ( 2 ) 129 - 138 .

Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Worthley SG ( 2015 ) . TCT-771 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Uncontrolled Hypertension and Chronic Kidney Disease: 12 Month Results from the EnligHTN II Study . Journal of the American College of Cardiology . vol. 66 , b313 - b314 .

Worthley SG, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Tsioufis KP, Papademetriou V et al. ( 2015 ) . TCT-774 Safety and Performance of the EnligHTN™ Renal Denervation System in Patients with Drug-resistant Hypertension: Pooled analyses from the EnligHTN I, II and III trials . Journal of the American College of Cardiology . vol. 66 ,

Lobo M, Montarello J, Saxena M, Jain A, Walters D, Pincus MW, Worthley SG ( 2015 ) . TCT-85 Safety and Performance of the EnligHTN Renal Denervation System in Patients with Severe Uncontrolled Hypertension: 12 Month Results from the EnligHTN II Study . Journal of the American College of Cardiology . vol. 66 , b39 - b40 .

Kapil V, Sobotka PA, Saxena M, Mathur A, Knight C, Dolan E, Stanton A, Lobo MD ( 2015 ) . Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation . Current Hypertension Reports vol. 17 , ( 9 )

Lobo M, Saxena M, Jain AJ, Walters D, Pincus M, Montarello J, Worthley SG ( 2015 ) . 4A.09 . Journal of Hypertension . vol. 33 ,

Saxena M, Collier D, Jain A, Knight C, Mathur A, Sobotka P, Lobo M ( 2015 ) . 8C.09 . Journal of Hypertension . vol. 33 ,

Antoniou S, Saxena M, Hamedi N, De Cates C, Moghul S, Lidder S, Lobo M, Kapil V ( 2015 ) . PP.21.35 . Journal of Hypertension . vol. 33 ,

Worthley S, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al. ( 2015 ) . PP.26.05 . Journal of Hypertension vol. 33 , ( &NA; )

Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S ( 2015 ) . PP.26.22 . Journal of Hypertension vol. 33 , ( &NA; )

Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S ( 2015 ) . PP.26.23 . Journal of Hypertension vol. 33 , ( &NA; ) e363 - e364 .

Antoniou S, Hamedi N, Lidder S, Saxena M, Brier T, Robinson P, Kapil V, Lobo M ( 2015 ) . CP-081 Management of uncontrolled blood pressure in patients with multiple drug intolerance referred to a specialist hypertension clinic . European Journal of Hospital Pharmacy vol. 22 , ( Suppl 1 )

Saxena M, Collier D, Jain A, Mathur A, Knight C, Sobotka P, Lobo M ( 2015 ) . A central iliac arteriovenous anastomosis results in durable and substantial blood pressure reduction in a woman with uncontrolled hypertension and multiple antihypertensive drug intolerances . JOURNAL OF HUMAN HYPERTENSION vol. 29 , ( 10 ) 631 - 632 .

Burchell AE, Chan K, Hart EC, Saxena M, Jain AK, Collier DJ, Paton JFR, Nightingale AK et al. ( 2015 ) . Challenges facing renal denervation: insight from real world experience at two UK centres . EUROPEAN HEART JOURNAL . vol. 36 , 505 - 506 .

Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S ( 2015 ) . SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH MODERATE UNCONTROLLED HYPERTENSION: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY . JOURNAL OF HYPERTENSION . vol. 33 , E363 - E364 .

Lobo M, Saxena M, Jain A, Walters D, Pincus M, Montarello J, Worthley S ( 2015 ) . SAFETY AND PERFORMANCE OF THE ENLIGHTN RENAL DENERVATION SYSTEM IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE: 12 MONTH RESULTS FROM THE ENLIGHTN II STUDY . JOURNAL OF HYPERTENSION . vol. 33 , E363 - E363 .

Worthley S, Montarello J, Saxena M, Jain A, Walters D, Pincus M, Tsioufis C, Papademetriou V et al. ( 2015 ) . SAFETY AND PERFORMANCE OF THE ENLIGHTN™ RENAL DENERVATION SYSTEM IN PATIENTS WITH DRUG-RESISTANT HYPERTENSION: POOLED ANALYSES FROM THE ENLIGHTN I, II AND III TRIALS . JOURNAL OF HYPERTENSION . vol. 33 , E359 - E359 .

Lobo MD, Montarello J, Saxena M, Jain AK, Walters D, Pincus M, Worthley SG ( 2015 ) . Safety and performance of the EnligHTN renal denervation system in patients with severe uncontrolled hypertension: 12 month results from the EnligHTN II Study . JOURNAL OF HUMAN HYPERTENSION vol. 29 , ( 10 ) 631 - 631 .

Saxena M, Antoniou S, Hamedi N, Chowdhury R, Lidder S, Brier T, Robinson P, Kapil V et al. ( 2014 ) . Anti-hypertensive medicine intolerance - an overlooked and important cause of failed compliance . JOURNAL OF HUMAN HYPERTENSION vol. 28 , ( 10 ) 633 - 633 .

Saxena M, Jain A, Mathur A, Knight C, Caulfield M, Collier D, Lobo M ( 2014 ) . Early reduction in blood pressure and heart rate variability following multielectrode radio-frequency renal denervation in medicines intolerant patients . JOURNAL OF HUMAN HYPERTENSION . vol. 28 , 647 - 647 .

Burchell A, Chan K, Ratcliffe L, Hart E, Saxena M, Collier D, Jain A, Mathur A et al. ( 2014 ) . Highly variable response to renal denervation for resistant hypertension - real world experience from 2 UK centres . JOURNAL OF HUMAN HYPERTENSION . vol. 28 , 645 - 646 .

Antoniou S, Hamedi N, Choudhury R, Lidder S, Saxena M, Brier T, Robinson P, Kapil V et al. ( 2014 ) . Management of uncontrolled blood pressure in patients referred to a specialist hypertension clinic with multiple medicines intolerance . JOURNAL OF HUMAN HYPERTENSION vol. 28 , ( 10 ) 645 - 645 .

Saxena M, Collier D, Caulfield M, Lobo M ( 2012 ) . Patients with resistant hypertension warrant a trial of salt restriction before and after renal denervation (RD) . JOURNAL OF HUMAN HYPERTENSION vol. 26 , ( 10 ) 619 - 619 .

Chan K, Ng FL, Saxena M, Collier D, Matson M, Jain A, Caulfield M, Lobo M ( 2012 ) . Renal denervation in resistant hypertension-a prospective case series . JOURNAL OF HUMAN HYPERTENSION vol. 26 , ( 10 ) 631 - 631 .

Collier DJ, Robson J, Scott R, Will CM, Eldridge SE, Griffiths CJ, Badrick E, Saxena M et al. ( 2010 ) . HiLo: a health services intervention study: methods and interim results on the first 2000 patients at 1 year . J HUM HYPERTENS vol. 24 , ( 10 ) 708 - 709 .